Observational studyJournal of medicine and life2026
Efficacy of high-dose serrapeptase (serratiopeptidase) in inflammation among orthopedic trauma patients.
Observational study in Journal of medicine and life, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pain and inflammation resulting from orthopedic trauma have a significant negative impact on early recovery and rehabilitation. A proteolytic enzyme called serrapeptase (serratiopeptidase), which has anti-inflammatory properties, has been used with increasing frequency in surgery and trauma-related surgery. Nevertheless, clinical evidence of its efficacy in orthopedic trauma remains scant. The objective of the study was to determine the effectiveness, safety, and tolerability of high-dose serrapeptase (serratiopeptidase; DANZ-N 30 mg) used as an adjunctive therapy in reducing inflammation and pain in patients with orthopedic trauma. This was a prospective, multicenter, real-world observational study that enrolled 850 patients with orthopedic trauma injuries. Group assignment was at the discretion of the treating physician: patients received either conventional trauma care alone or conventional trauma care combined with oral serrapeptase. Pain intensity was assessed using a Visual Analog Scale (VAS), and inflammatory changes were systematically monitored over 15 days. Adverse events were systematically recorded to assess safety. In total, 408 patients in the serrapeptase group and 405 in the conventional-treatment group completed the study. VAS scores declined significantly faster in the serrapeptase group, with a mean difference of 1.4 points by day 15 (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.